Prof Jerome De Seze MD, PhD

Jerome de Seze
50 years-old
Professor in Neurology
PhD in Immunology
Head of the Neuroimmunological department of the Strasbourg hospital, specialized in Multiple sclerosis and Neuro-ophthalmology
Head of the clinical research center (CIC) of the Strasbourg hospital
Head of the DHU (Department Hospital/University called Neurogenics).
Co-leader of the research team of biopathology of the myelin neuroprotection and therapeutical strategy (BMNST), INSERM laboratory UMR 1119
President of the French Multiple Sclerosis society

Main interest : clinical and research works in inflammatory and autoimmune diseases of CNS and PNS. Neuro-ophtalmology.

Has published more than 300 papers

10 more relevant papers from the last 5 years :

  1. Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Seze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M; Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (BIONAT), Best EScalation Treatment in Multiple Sclerosis (BEST-MS), and the Société Francophone de la Sclérose En Plaques (SFSEP) Network.Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. Ann Neurol. 2017;82(2):186-195.
  2. Brochet B, Deloire MS, Perez P, Loock T, Baschet L, Debouverie M, Pittion S, Ouallet JC, Clavelou P, de Seze J, Collongues N, Vermersch P, Zéphir H, Castelnovo G, Labauge P, Lebrun C, Cohen M, Ruet A; PROMESS study investigators. Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. PLoS One. 2017 Jan 3;12(1)
  3. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):209-220.
  4. Maillart E, Vidal JS, Brassat D, Stankoff B, Fromont A, de Seze J, Taithe F, Clavelou P, Bourre B, Delvaux V, Rico A, Labauge P, Tourbah A, Lebrun C, Pelletier J, Moreau T, Louapre C, Lubetzki C, Papeix C.Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome. Neurol Neuroimmunol Neuroinflamm. 2017;14;4(3)
  5. Brun S, Beaino W, Kremer L, Taleb O, Mensah-Nyagan AG, Lam CD, Greer JM,de Seze J, Trifilieff E. Characterization of a new rat model for chronic inflammatory demyelinating polyneuropathies.J Neuroimmunol. 2015;278:1-10.
  6. Pröbstel AK, Rudolf G, Dornmair K, Collongues N, Chanson JB, Sanderson NS, Lindberg RL, Kappos L, de Seze J, Derfuss T. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation. 2015;12(1):46.
  7. Fox RJ, Cree BA, de Seze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology. 2014 Apr 29;82(17):1491-8
  8. Sato DK, Lana-Peixoto MA, Fujihara K,de Seze J. Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status.Brain Pathol. 2013;23(6):647-60.
  9. Moussallieh FM, Elbayed K, Chanson JB, Rudolf G, Piotto M,de Seze J, Namer IJ.Serum analysis by 1H nuclear magnetic resonance spectroscopy: a new tool for distinguishing neuromyelitis optica from multiple sclerosis. Mult Scler. 2014;20(5):558-65
  10. Kremer S, Lamy J, Magnus A, Oesterle H, Jeantroux J, Trunet S, Armspach JP, Dietemann JL, de Seze J. Evaluation of an albumin-binding gadolinium contrast agent in multiple sclerosis.Neurology. 2013;81(3):206-10.